Novartis AG (NVS)
| Previous Close | 97.09 |
| Open | 97.08 |
| Bid | 97.64 x 800 |
| Ask | 97.63 x 800 |
| Day's Range | 96.93 - 97.82 |
| 52 Week Range | 92.19 - 108.78 |
| Volume | |
| Avg. Volume | 1,648,904 |
| Market Cap | 199.706B |
| Beta (5Y Monthly) | 0.47 |
| PE Ratio (TTM) | 22.21 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.78 (3.89%) |
| Ex-Dividend Date | Mar 07, 2024 |
| 1y Target Est | N/A |
- GlobeNewswire
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
There is currently no evidence-based treatment for the smallest babies with malaria The CALINA study tested a new ratio and dose of Coartem® (artemether- lumefantrine) to account for metabolic differences in babies under 5 kg The CALINA trial indicated that the new formulation has good efficacy and safety, and the data have been submitted for regulatory review Basel, April 24, 2024 – Novartis and Medicines for Malaria Venture (MMV) announce positive data from their phase II/III CALINA study, dem
- GlobeNewswire
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare cancer that is often unresectable and commonly diagnosed in the late stages of diseaseNovartis, a leader in radioligand therapy (RLT), is investigating a portfolio of RLTs to treat a broad range of cancers, including GEP-NETs, lung, prostate, breast, colon, bra
- GlobeNewswire
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
Ad hoc announcement pursuant to Art. 53 LRQ1 net sales grew +11% (cc1, +10% USD) with core operating income up +22% (cc, +16% USD) Key growth drivers continued strong sales momentum including Entresto (+36% cc), Cosentyx (+25% cc), Kesimpta (+66% cc), Kisqali (+54% cc), Pluvicto (+47% cc) and Leqvio (+139% cc)Core operating income margin 38.4%, +340 basis points (cc), mainly driven by higher net salesOperating income grew +39% (cc, +29% USD) and net income grew +37% (cc, +25% USD), mainly driven
